drugset
drugset / Trial / NCT05953740

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

NCT05953740 ↗

Phase 1 Completed 17 enrolled Merck Sharp & Dohme LLC
RandomizedSequentialTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of single ascending intramuscular doses of MK-5720, and the safety and tolerability of multiple once-daily oral doses of MK-8189, in participants with schizophrenia. The primary study hypothesis is that the administration of MK-5720 is safe and well tolerated.

Timeline

Start
2023-09-15
Primary completion
2024-02-15
Completion
2024-02-15

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-5720 Unknown 35 mg Intramuscular
Subject MK-5720 Unknown 70 mg Intramuscular
Subject MK-5720 Unknown 140 mg Intramuscular
Subject MK-5720 Unknown 280 mg Intramuscular
Subject MK-5720 Unknown 560 mg Intramuscular
Subject MK-8189 Small molecule 4 mg Oral
Subject MK-8189 Small molecule 8 mg Oral
Subject MK-8189 Small molecule 16 mg Oral
Subject MK-8189 Small molecule 24 mg Oral
Subject MK-8189 Small molecule 48 mg Oral

Indications

schizophrenia